Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(2.98)
# 1,560
Out of 5,008 analysts
77
Total ratings
39.51%
Success rate
2.3%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GNFT Genfit | Maintains: Buy | $9 → $7 | $3.96 | +76.77% | 2 | Sep 24, 2025 | |
| RNTX Rein Therapeutics | Initiates: Buy | $10 | $1.44 | +594.44% | 1 | Sep 22, 2025 | |
| MNKD MannKind | Reiterates: Buy | $11 | $5.65 | +94.69% | 5 | Sep 18, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $93 → $121 | $91.68 | +31.98% | 6 | Sep 17, 2025 | |
| VALN Valneva SE | Reiterates: Buy | $18 | $10.65 | +69.01% | 2 | Aug 25, 2025 | |
| DERM Journey Medical | Initiates: Buy | $13 | $7.55 | +72.19% | 2 | Aug 25, 2025 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $12 | $3.32 | +261.45% | 2 | Aug 21, 2025 | |
| EPRX Eupraxia Pharmaceuticals | Reiterates: Buy | $12 | $6.02 | +99.34% | 3 | Aug 20, 2025 | |
| PYPD PolyPid | Reiterates: Buy | $13 | $3.33 | +290.39% | 4 | Aug 13, 2025 | |
| CNTB Connect Biopharma Holdings | Reiterates: Buy | $7 | $1.78 | +293.26% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $10 | $8.28 | +20.77% | 1 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $44 | $33.39 | +31.78% | 6 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $11.09 | +53.29% | 3 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $29 | $7.34 | +295.10% | 1 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $23.72 | +18.04% | 1 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $11.08 | +80.51% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $10.19 | +155.15% | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.32 | +354.55% | 2 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $5 | $2.08 | +140.38% | 2 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.06 | +749.06% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $9.55 | +119.90% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.19 | +320.17% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $4.44 | +102.70% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.39 | +1,954.44% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $9.92 | +61.29% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.50 | +1,901.20% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $18.23 | +2,395.89% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $30.33 | +94.53% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $137.32 | +31.08% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $4.35 | +4,957.47% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $30.95 | +3.39% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $1.88 | +1,170,112.77% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $15.02 | +232.89% | 1 | Jul 12, 2018 |
Genfit
Sep 24, 2025
Maintains: Buy
Price Target: $9 → $7
Current: $3.96
Upside: +76.77%
Rein Therapeutics
Sep 22, 2025
Initiates: Buy
Price Target: $10
Current: $1.44
Upside: +594.44%
MannKind
Sep 18, 2025
Reiterates: Buy
Price Target: $11
Current: $5.65
Upside: +94.69%
ANI Pharmaceuticals
Sep 17, 2025
Maintains: Buy
Price Target: $93 → $121
Current: $91.68
Upside: +31.98%
Valneva SE
Aug 25, 2025
Reiterates: Buy
Price Target: $18
Current: $10.65
Upside: +69.01%
Journey Medical
Aug 25, 2025
Initiates: Buy
Price Target: $13
Current: $7.55
Upside: +72.19%
Achieve Life Sciences
Aug 21, 2025
Initiates: Buy
Price Target: $12
Current: $3.32
Upside: +261.45%
Eupraxia Pharmaceuticals
Aug 20, 2025
Reiterates: Buy
Price Target: $12
Current: $6.02
Upside: +99.34%
PolyPid
Aug 13, 2025
Reiterates: Buy
Price Target: $13
Current: $3.33
Upside: +290.39%
Connect Biopharma Holdings
Aug 13, 2025
Reiterates: Buy
Price Target: $7
Current: $1.78
Upside: +293.26%
Aug 12, 2025
Assumes: Buy
Price Target: $10
Current: $8.28
Upside: +20.77%
Aug 11, 2025
Assumes: Buy
Price Target: $44
Current: $33.39
Upside: +31.78%
Aug 8, 2025
Maintains: Buy
Price Target: $20 → $17
Current: $11.09
Upside: +53.29%
Aug 7, 2025
Assumes: Buy
Price Target: $29
Current: $7.34
Upside: +295.10%
Aug 6, 2025
Initiates: Buy
Price Target: $28
Current: $23.72
Upside: +18.04%
Jul 28, 2025
Assumes: Buy
Price Target: $20
Current: $11.08
Upside: +80.51%
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $10.19
Upside: +155.15%
Jun 9, 2025
Initiates: Buy
Price Target: $6
Current: $1.32
Upside: +354.55%
Jun 5, 2025
Assumes: Buy
Price Target: $5
Current: $2.08
Upside: +140.38%
Jun 2, 2025
Initiates: Buy
Price Target: $9
Current: $1.06
Upside: +749.06%
May 28, 2025
Initiates: Buy
Price Target: $21
Current: $9.55
Upside: +119.90%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $1.19
Upside: +320.17%
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $4.44
Upside: +102.70%
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.39
Upside: +1,954.44%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $9.92
Upside: +61.29%
Jun 13, 2024
Initiates: Buy
Price Target: $10
Current: $0.50
Upside: +1,901.20%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $18.23
Upside: +2,395.89%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $30.33
Upside: +94.53%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $137.32
Upside: +31.08%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $4.35
Upside: +4,957.47%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $30.95
Upside: +3.39%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $1.88
Upside: +1,170,112.77%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $15.02
Upside: +232.89%